These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17060972)

  • 1. Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas.
    Capizzi RL
    Trans Am Clin Climatol Assoc; 2004; 115():255-72. PubMed ID: 17060972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
    J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
    Zelenetz AD
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
    Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
    Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
    J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The radioisotope contributes significantly to the activity of radioimmunotherapy.
    Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
    Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
    Vose JM
    Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
    Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
    J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
    Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
    J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens.
    Nordøy T; Kolstad A; Tuck MK; Aaberge IS; Husebekk A; Kaminski MS
    Clin Immunol; 2001 Jul; 100(1):40-8. PubMed ID: 11414744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
    Wahl RL
    J Nucl Med; 2005 Jan; 46 Suppl 1():128S-40S. PubMed ID: 15653661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies in radioimmunotherapy for lymphoma.
    Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
    Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
    White CA
    J Exp Ther Oncol; 2004 Dec; 4(4):305-16. PubMed ID: 15844660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.